Skip to main content
LIGAND PHARMACEUTICALS INC logo

LIGAND PHARMACEUTICALS INC — Investor Relations & Filings

Ticker · LGND ISIN · US53220K5048 LEI · 5493008K7TB0IKP37H79 US Financial and insurance activities
Open in API
Filings indexed 1,392 across all filing types
Latest filing 2011-02-10 Major Shareholding Noti…
Country US United States of America
Listing US LGND

About LIGAND PHARMACEUTICALS INC

https://www.ligand.com/

Ligand Pharmaceuticals Incorporated is a biopharmaceutical company that functions as a capital and technology partner to the life sciences industry. The company's business model focuses on acquiring and developing royalty-generating assets by investing in the clinical development and commercialization of medicines. It manages a large, diverse portfolio of economic rights to partnered programs across therapeutic areas such as oncology, kidney disease, diabetes, and rare conditions. In addition to its royalty business, Ligand develops and licenses its proprietary technology platforms to a global network of biopharmaceutical partners. Its key technologies include Captisol®, a chemically modified cyclodextrin used to improve the solubility and stability of active pharmaceutical ingredients, and the NITRICIL™ platform.

Recent filings

Filing Released Lang Actions
SC 13G Filing
Major Shareholding Notification
2011-02-10 English
3 Filing
Director's Dealing
2011-02-10 English
8-K Filing
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is used for current reports on significant events. The content specifically announces the appointment of a new director to the Board of Directors. This matches the description of Board/Management Information filings, which cover announcements of changes in the company's board or senior management. The document is not a full annual or quarterly report, nor is it an earnings release or other financial report. It is not a proxy statement or voting results announcement. Therefore, the appropriate classification is MANG (Board/Management Information). The document length is 3663 characters, which is consistent with a typical 8-K filing for management changes. Confidence is high due to clear and explicit content about director appointment.
2011-02-09 English
SC 13G/A Filing
Major Shareholding Notification
2011-01-31 English
8-K Filing
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events that shareholders should know about. The text includes details about a License Agreement entered into by Ligand Pharmaceuticals, amendments to a Contingent Value Rights Agreement, and other corporate events. It does not contain comprehensive financial statements or detailed financial performance data typical of Annual Reports (10-K) or Interim Reports (IR). It also is not a transcript, proxy statement, or remuneration report. The document is a regulatory filing announcing material corporate events and agreements, consistent with the definition of Regulatory Filings (RNS). The document length (9269 characters) and content confirm it is not merely a brief announcement but a detailed current report, yet it does not fit into more specific categories like M&A filings or capital updates. Therefore, the best classification is Regulatory Filings (RNS).
2011-01-31 English
8-K Filing
Board/Management Information Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated January 26, 2011. It reports the payment of bonuses to named executive officers, which is a disclosure related to management compensation and changes. The content focuses on executive bonuses approved by the Board, which aligns with announcements about management or board-related information. The document is short (3166 characters) and does not contain financial statements or detailed financial data, so it is not an Annual Report, Earnings Release, or Interim Report. It is not a proxy statement or remuneration report but rather a specific announcement about management compensation decisions. Therefore, the best fitting category is Board/Management Information (MANG).
2011-01-28 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.